Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

essential medicines

- PMLiVE

India’s patents versus India’s patients

What the Roche Pegasys case means for big pharma

- PMLiVE

UK inactivity on value-based pricing plan damaging, say MPs

Health Committee report also highlights needs to address end of the cancer drugs fund

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

- PMLiVE

India’s Supreme Court wants tighter clinical trial regulation

Justice Lodha says illegal studies of investigational medicines causing “havoc to human life”

- PMLiVE

Lilly pays $29m to settle foreign bribery charges

US Securities and Exchange Commission charges centre on activities in Russia, China, Brazil and Poland

- PMLiVE

India revokes patent on Merck asthma drug

Cipla breaks one more of the pharma company's patents

- PMLiVE

India approves national drug pricing scheme

Adds around 350 new drugs to the country's essential medicines list

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

- PMLiVE

Depth perception: diabetes in India

Using digital, pharma can engage with diabetes patients in India and build a 3D image of their needs

ICC Lowe expands to India through LinHealth partnership

Strategic partnership will operate as ICC Lowe LinHealth in India

- PMLiVE

India revokes Roche’s Pegasys patent after patient group challenge

Company becomes latest in big pharma to see intellectual property overturned

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links